⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
High antipsychotic prescribing (65+)
Risk indicators are statistical patterns, not allegations. Learn more
9,607
Total Claims
$2.0M
Drug Cost
902
Beneficiaries
$2,211
Cost/Patient
Risk Score Breakdown 12/100
Low (0)Moderate (15)Elevated (30)High (50+)
Elderly antipsychotic prescribing+10
Score components are additive. Read full methodology
Peer Comparison vs. 13,194 Neurology providers
-45%
Cost per patient vs peers
$2,211 vs $4,034 avg
+19%
Brand preference vs peers
11.2% vs 9.4% avg
Brand vs Generic
89% generic
Brand: 1,066 claims · $1.6M
Generic: 8,479 claims · $425K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Ubrogepant | 141 | $180K |
| Rimegepant Sulfate | 112 | $160K |
| Interferon Beta-1a/Albumin | 13 | $142K |
| Galcanezumab-Gnlm | 162 | $141K |
| Erenumab-Aooe | 161 | $139K |
| Interferon Beta-1a | 14 | $127K |
| Brivaracetam | 62 | $122K |
| Glatiramer Acetate | 20 | $88K |
| Pimavanserin Tartrate | 11 | $85K |
| Immune Globul G/Gly/Iga Avg 46 | 19 | $84K |
| Atogepant | 44 | $57K |
| Galcanezumab-Gnlm | 49 | $47K |
| Cenobamate | 41 | $42K |
| Glatiramer Acetate | 14 | $34K |
| Lacosamide | 157 | $26K |
Prescribing Profile
Patient Profile
69
Avg Age
62%
Female
1.47
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About